Cidara Therapeutics (CDTX) Registration Filing summary

Company overview and business model

• Focuses on developing drug-Fc conjugate therapeutics using the proprietary Cloudbreak® platform for serious diseases.

• Lead asset CD388 is a long-acting antiviral for broad-spectrum influenza prophylaxis, designed to provide universal protection against all influenza A and B strains.

• CD388 was reacquired from Janssen in April 2024, with an exclusive, worldwide, royalty-free license for development and commercialization.

• Completed divestiture of rezafungin in April 2024 to focus resources solely on CD388.

• Currently conducting a 5,041-subject Phase 2b trial (NAVIGATE study) for CD388, with top-line data expected in late June 2025.

Financial performance and metrics

• Raised $240 million in gross proceeds from a private placement in April 2024, using $85 million for the Janssen license upfront payment.

• Additional $105 million raised in November 2024, with remaining funds allocated to ongoing CD388 development.

• Net tangible book value as of March 31, 2025, was $141.7 million ($11.60 per share).

• After a $150 million offering at $18.98 per share, as adjusted net tangible book value would be $286.5 million ($14.25 per share), with immediate dilution of $4.73 per share to new investors.

Use of proceeds and capital allocation

• Net proceeds from securities sales will primarily fund continued R&D of pipeline product candidates, working capital, capital expenditures, and general corporate purposes.

• May use a portion of proceeds for acquisitions of complementary businesses, products, or technologies, though no current plans exist.

• Pending use, proceeds may be invested in short-term, investment-grade, interest-bearing securities or held as cash.